Luke M. Beshar, C.P.A.

Luke M. Beshar is an experienced biopharmaceutical executive and financial expert. During his tenure at NPS Pharmaceuticals, Mr. Beshar oversaw financial management, investor relations, technical operations, information technology, quality assurance, project management, contracts & outsourcing and facilities. Prior to this role, he served as Executive Vice President, Strategy and Corporate Development and Chief Financial Officer of Cambrex Corporation and as Chief Financial Officer of Dendrite International.

Earlier in his career, Mr. Beshar held various general and financial management positions of increasing responsibility. He began his career at Arthur Anderson & Co. and is a Certified Public Accountant. Currently, Mr. Beshar serves on the Board of Directors of Protara Therapeutics and Inotrem. From 2014 until it was acquired by Pfizer in November 2021, he served as a director and was chair of the audit and compensation committees at Trillium Therapeutics Inc.  From 2015 to 2021, Mr. Beshar served as a director and chair of audit committee of REGENXBIO Inc.

Mr. Beshar holds a B.S. in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia and is a Certified Public Accountant.